Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab
Sign Up to like & getrecommendations! Published in 2019 at "Advances in Rheumatology"
DOI: 10.1186/s42358-019-0097-1
Abstract: BackgroundTocilizumab (TCZ), a humanized monoclonal antibody against the interleukin-6 receptor, has been proven to be a safe and effective treatment for rheumatoid arthritis (RA). Because RA is a heterogenous disease and patient response to treatments… read more here.
Keywords: response; disease; cxcl13 sicam; cxcl13 ... See more keywords